Tomasz Beer, MD

Articles

Expanding Cancer Screening: The Future of Blood-Based Testing

November 21st 2023

Closing out their panel, experts discuss the potential of blood-based tests to democratize access to cancer screening, complement existing protocols, and achieve early detection goals in the fight against cancer.

Future of Multi-Cancer Early Detection: A Recap and Horizon

November 21st 2023

Elizabeth O’Donnell, MD, and Tomasz Beer, MD, FACP, recap key takeaways from the panel and consider the potential of MCED testing in transforming cancer screening and addressing gaps in early detection.

Moonshot Cancer Initiative and MCED Consortium: Advancing Cancer Detection

November 14th 2023

Explore the pivotal role of the Moonshot Cancer Initiative and MCED Consortium in shaping the landscape of early cancer detection and screening, with a focus on innovative screening tools and legislative support.

Future Needs and Challenges of Multi-Cancer Early Detection Tests

November 14th 2023

Implementation challenges and the importance of equitable access in the future of multi-cancer early detection tests.

Efficiency in Diagnostic Resolution: Imaging vs. Molecular Tissue of Origin

November 7th 2023

Shared insight into the efficiency of diagnostic resolution approaches, comparing imaging-based and molecular tissue of origin strategies in multi-cancer early detection testing.

Advancing Cancer Detection With the ASCEND Trial: Key Objectives and Rationale

November 7th 2023

Expert perspectives about the ASCEND trial, its study design, and the critical role it plays in developing advanced cancer detection methods.

Advancements in Multi-Biomarker Cancer Testing

October 31st 2023

Key opinion leaders review the rationale behind multi-biomarker approaches and how they're shaping the future of cancer detection and research.

Cancer Screening Breakthroughs: Implications for Clinical Practice

October 31st 2023

Discover the potential clinical implications of groundbreaking cancer screening studies, DETECT-A and PATHFINDER, and the evolving landscape of multi-cancer early detection.

Latest Insights from the PATHFINDER Study: Cancer Detection Advancements

October 24th 2023

Panelists explore recent findings of the PATHFINDER study, focusing on the objectives, study design, key results, and differences from previous studies, shedding light on the potential of early cancer detection tests.

DETECT-A Study: Advancements in Early Cancer Detection

October 24th 2023

Shared insight into findings of the DETECT-A study, a prospective interventional trial, covering feasibility, safety, and performance of multicancer early detection tests in a healthcare system setting.

Addressing Healthcare Inequity With Accessible Multicancer Early Detection

October 17th 2023

The potential of MCED testing to reduce health inequities and an examination of accessibility, including FDA approval, physician education, patient awareness, affordability, and logistical support.

The Transformative Potential of Multicancer Early Detection Testing

October 17th 2023

Expert panelists delve into multicancer early detection testing and discuss its potential to revolutionize cancer screening, close healthcare gaps, and complement standard care approaches.

Addressing Health Inequities in Cancer Screening: Challenges and Opportunities

September 29th 2023

Explore critical issues surrounding health disparities in cancer screening, as discussed by experts, and the urgent need to bridge gaps in access, trust, and follow-up care for underserved populations.

Cancer Screening and Management: Overview of the Current Landscape

September 29th 2023

A panel of esteemed cancer experts explore the challenges and opportunities in cancer screening and identification, shedding light on the evolving landscape and its impact on clinical practice.

Dr. Beer on the Immune-Related Adverse Events of Ipilimumab in mCRPC

May 16th 2014

Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.

Dr. Beer on the Implications of the PREVAIL Study

February 3rd 2014

Tomasz Beer, MD, FACP, professor of Medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, discusses the treatment of metastatic castration-resistant prostate cancer (mCRPC) with abiraterone and enzalutamide as it relates to results from the PREVAIL study.